Ebola Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The ebola vaccine market size is projected to be USD 2.30 billion in 2025, USD 2.42 billion in 2026, and reach USD 3.27 billion by 2031, growing at a CAGR of 6.17% from 2026 to 2031. This report is Segmented by Vaccine Type (Recombinant Vector Vaccine, Inactivated Virus Vaccine, DNA Vaccine, Subunit Vaccine, Others), End User (Hospitals, Government Health Departments, Research Institutes, Ngos, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Ebola Vaccine Market Trends and Insights

Gavi-Funded Global Stockpile Ensures Institutional Demand and Rapid Deployment

Gavi’s 500,000-dose stockpile and its 2024 preventive-funding window moved the Ebola Vaccine market away from pure outbreak response. Between 2021-2023, 95% of Gavi shipments were preventive, confirming that endemic countries now place standing orders for healthcare-worker immunization. The September 2025 market-shaping roadmap locked in volume commitments through 2030, giving manufacturers forward-visibility and stabilizing the Ebola Vaccine market size. Allocation protocols reward pre-qualified suppliers with rapid fill-finish capacity, reinforcing incumbent advantages. Compliance with WHO prequalification and ICH Q7 GMP remains compulsory for stockpile participation.

Recurring Outbreaks and Ring Vaccination Standard Sustain Outbreak-Driven Demand

Uganda’s February 2025 Sudan ebolavirus episode and DRC’s September 2025 Kasai flare-up illustrate persistent zoonotic spill-over that triggers ring vaccination. Each deployment consumes 3,000-10,000 doses, supporting a baseline of roughly 50,000 outbreak-response doses per year. Inter-outbreak intervals in DRC have shortened to 1.8 years since 2018, underlining a structural demand driver for the Ebola Vaccine market. Absence of a licensed Sudan vaccine, however, limits effectiveness outside Zaire outbreaks.

Small, Sporadic Addressable Population Limits Commercial Scale

Cumulative confirmed Ebola cases remain below 35,000, capping peak annual volume at roughly 300,000 doses when stockpile rotation is included. Fixed costs for prequalification and cold-chain validation exceed USD 50 million, yet tiered Gavi pricing keeps peak revenue per supplier under USD 150 million, tempering private investment. The Sudan vaccine gap persists largely because expected returns do not offset Phase III trial costs estimated at USD 80-120 million .

Other drivers and restraints analyzed in the detailed report include:

• Regulatory Approvals and WHO Prequalification Expand Eligible Populations
• Preventive Vaccination for HCW/FLW Supported by SAGE and Gavi Expands Use Cases
• Ultra-Cold Chain Requirements Complicate Last-Mile Logistics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Recombinant vectors controlled 62.3% of 2025 Ebola Vaccine market share on the back of ERVEBO’s single-dose convenience and 97.5% efficacy. Despite ultra-cold storage hurdles, predictable Gavi rotation keeps demand steady. The segment anchors over half of the 2026 Ebola Vaccine market size and maintains entrenched first-mover advantages.

Inactivated virus products are forecast to expand at a 7.23% CAGR, propelled by Chinese and Indonesian programs targeting thermostable formulations for domestic stockpiles. DNA and subunit approaches remain niche due to device costs and early-stage pipelines, yet they illustrate technology diversification that could reshape the Ebola Vaccine market if cold-chain barriers persist. Zabdeno/Mvabea’s two-dose adenovirus platform carves out niches among immunocompromised groups but sacrifices outbreak agility. Regulatory lead times and prequalification costs continue to shield incumbents, making thermostability the clearest path for newcomers to capture Ebola Vaccine market share.

Complete Report Scope:

• By Vaccine Type
  • Recombinant Vector Vaccine
  • Inactivated Virus Vaccine
  • DNA Vaccine
  • Subunit Vaccine
  • Others
• By End User
  • Hospitals
  • Government Health Departments
  • Research Institutes
  • NGOs
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America’s 46% share in 2025 reflects robust preparedness funding rather than local incidence. The U.S. Strategic National Stockpile maintains roughly 50,000 doses, and CDC guidelines institutionalize annual replenishment. Canada upgraded its reserve to 10,000 doses in 2025 following lessons from Uganda’s outbreak, embedding ring-vaccination protocols into its response plan. Mexico’s role is confined to laboratory immunization. Regulatory rigor under FDA and OSHA ensures that only pre-qualified suppliers penetrate the Ebola Vaccine market here.

Asia-Pacific is the fastest-growing region, with a 7.5% CAGR. Japan invested USD 18 million in 2024 for 20,000 ERVEBO doses and freezer upgrades, while South Korea aims to secure 15,000 doses by 2027. China’s inactivated candidate could localize supply by 2026, consistent with Healthy China 2030 self-sufficiency mandates. India’s demand remains limited to laboratory staff, yet guidelines published in 2025 lay the groundwork for broader adoption. Australia’s National Medical Stockpile keeps 5,000 doses for BSL-4 facilities.

Europe accounted for a significant share of 2025 spending. Germany leads with 25,000 doses, followed by the United Kingdom at 18,000, all coordinated through ECDC’s Health Security Committee. EMA authorization of Zabdeno/Mvabea adds platform diversity but uptake outside stockpiles is minimal. Africa and the Middle East rely heavily on Gavi: the Africa CDC initiative aims to pre-position 100,000 doses by 2027 and establish fill-finish capability in Dakar. South American participation remains research-focused, led by Brazil’s Fiocruz with a 2,500-dose reserve.

List of Companies Covered in this Report:

• Arisan Therapeutics
• Auro Vaccines
• Bharat Biotech
• Bio Farma
• China Immunotech
• Emergent Bio Solutions
• GlaxoSmithKline
• Inovio Pharmaceuticals
• Johnson & Johnson
• Merck
• RedHill Biopharma
• Regeneron Pharmaceuticals
• Takeda Pharmaceuticals
• TFF Pharmaceuticals
• Viralytics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support